ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss)"

  • Abstract Number: 1599 • ACR Convergence 2024

    Glucocorticoids versus Glucocorticoids Plus Cyclophosphamide in Eosinophilic Granulomatosis with Polyangiitis with Poor-Prognosis Factors: A Target Trial Emulation Study

    Boris Sorin1, Matthias Papo1, Renato Alberto Sinico2, Vítor Silvestre Teixeira3, Nils Venhoff4, Maria-Letizia Urban5, Michele Iudici6, Juliane Mahrhold7, Francesco Locatelli8, Giulia Cassone9, Franco Schiavon10, Benjamin Seeliger11, Thomas Neumann12, Claudia Feder13, Claus Kroegel14, Matthieu Groh15, Chiara Marvisi16, Maxime Samson17, Thomas Barba18, David Jayne19, Arianna Troilo20, Jens Thiel20, Bernhard Hellmich21, Sara Monti22, Carlomaurizio Montecucco23, Carlo Salvarani24, Jean-Emmanuel Kahn25, Bernard Bonnotte26, Cécile-Audrey Durel27, Xavier Puéchal28, Luc Mouthon29, Loïc Guillevin30, Giacomo Emmi31, Augusto Vaglio32, Raphael Porcher33 and Benjamin Terrier34, and the French Vasculitis Study Group (FVSG) and the European EGPA Study Group (EESG), 1Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases of Ile de France, East and West, Paris Cité University, Assistance Publique – Hôpitaux de Paris, Paris, France, 2Nephrology and Dialysis Unit, IRCCS Humanitas Research Hospital, Milan, Italy, 3Department of Rheumatology, Faro Hospital, Algarve, Portugal, 4Medical Center - University of Freiburg, Internal Medicine, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, 5Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 6Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases of Ile de France, East and West, Paris Cité University, Assistance Publique – Hôpitaux de Paris and Division of rheumatology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland, Paris, France, 7Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabtologyy and Immunology, ERN-RITA Reference Center, Vasculitis-Center Tübingen-Kirchheim, Medius Kliniken Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, 8Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, 9Clinical and Experimental Medicine PhD Program, Azienda USL-IRCCS di Reggio Emilia and Universita di Modena and Reggio Emilia, Modena, Italy, 10Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, 11Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, 12Department of Rheumatology, Clinic of Internal Medicine III, Jena University Hospital, Jena, Germany and Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St Gallen, St Gallen, Switzerland, Jena, Germany, 13Department of Rheumatology, Clinic of Internal Medicine III, Jena University Hospital, Jena, Germany, 14Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany, 15Foch, Suresnes, France, 16Rheumatology Unit Universita di Modena and Reggio Emilia, Modena, Italy, 17Department of Internal Medicine and Clinical Immunology, François-Mitterrand Teaching Hospital, University of Bourgogne-Franche-Comté, Dijon, France, 18Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, 19University of Cambridge, Cambridge, United Kingdom, 20Department of Rheumatology and Clinical Immunology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany, 21Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, 22IRCCS Istituto Auxologico Italiano, Milan, Italy, 23IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 24Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, 25Department of Internal Medicine, Ambroise Paré Hospital, Assistance Publique - Hôpitaux de Paris, Université de Versailles Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France, Boulogne Billancourt, France, 26Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France., Dijon, France, 27Edouard Herriot University Hospital, Lyon, France, 28National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 29Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l'Est et de l'Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 30National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, 31Department of Medical, Surgery and Health Sciences, University of Trieste, and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, 32Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Florence, Italy, 33Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, 34Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel necrotizing vasculitis characterized by asthma, blood and tissue eosinophilia and vasculitis affecting multiple organs. According to…
  • Abstract Number: 1600 • ACR Convergence 2024

    Glucocorticoids versus Glucocorticoids Plus Cyclophosphamide in Eosinophilic Granulomatosis with Polyangiitis Without Poor-Prognosis Factors: A Target Trial Emulation Study

    Boris Sorin1, Matthias Papo1, Renato Alberto Sinico2, Vítor Silvestre Teixeira3, Nils Venhoff4, Maria-Letizia Urban5, Michele Iudici6, Juliane Mahrhold7, Francesco Locatelli8, Giulia Cassone9, Franco Schiavon10, Benjamin Seeliger11, Thomas Neumann12, Claudia Feder13, Claus Kroegel14, Matthieu Groh15, Chiara Marvisi16, Maxime Samson17, Thomas Barba18, David Jayne19, Arianna Troilo20, Jens Thiel20, Bernhard Hellmich21, Sara Monti22, Carlomaurizio Montecucco23, Carlo Salvarani24, Jean-Emmanuel Kahn25, Bernard Bonnotte26, Cécile-Audrey Durel27, Xavier Puéchal28, Luc Mouthon29, Loïc Guillevin30, Giacomo Emmi31, Augusto Vaglio32, Raphael Porcher33 and Benjamin Terrier34, and the French Vasculitis Study Group (FVSG) and the European EGPA Study Group (EESG), 1Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases of Ile de France, East and West, Paris Cité University, Assistance Publique – Hôpitaux de Paris, Paris, France, 2Nephrology and Dialysis Unit, IRCCS Humanitas Research Hospital, Milan, Italy, 3Department of Rheumatology, Faro Hospital, Algarve, Portugal, 4Medical Center - University of Freiburg, Internal Medicine, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, 5Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 6Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases of Ile de France, East and West, Paris Cité University, Assistance Publique – Hôpitaux de Paris and Division of rheumatology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland, Paris, France, 7Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabtologyy and Immunology, ERN-RITA Reference Center, Vasculitis-Center Tübingen-Kirchheim, Medius Kliniken Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, 8Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, 9Clinical and Experimental Medicine PhD Program, Azienda USL-IRCCS di Reggio Emilia and Universita di Modena and Reggio Emilia, Modena, Italy, 10Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, 11Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, 12Department of Rheumatology, Clinic of Internal Medicine III, Jena University Hospital, Jena, Germany and Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St Gallen, St Gallen, Switzerland, Jena, Germany, 13Department of Rheumatology, Clinic of Internal Medicine III, Jena University Hospital, Jena, Germany, 14Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany, 15Foch, Suresnes, France, 16Rheumatology Unit Universita di Modena and Reggio Emilia, Modena, Italy, 17Department of Internal Medicine and Clinical Immunology, François-Mitterrand Teaching Hospital, University of Bourgogne-Franche-Comté, Dijon, France, 18Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, 19University of Cambridge, Cambridge, United Kingdom, 20Department of Rheumatology and Clinical Immunology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany, 21Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, 22IRCCS Istituto Auxologico Italiano, Milan, Italy, 23IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 24Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, 25Department of Internal Medicine, Ambroise Paré Hospital, Assistance Publique - Hôpitaux de Paris, Université de Versailles Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France, Boulogne Billancourt, France, 26Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France., Dijon, France, 27Edouard Herriot University Hospital, Lyon, France, 28National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 29Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l'Est et de l'Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 30National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, 31Department of Medical, Surgery and Health Sciences, University of Trieste, and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, 32Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Florence, Italy, 33Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, 34Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, blood and tissue eosinophilia and vasculitis affecting multiple organs. According to the…
  • Abstract Number: 1601 • ACR Convergence 2024

    Changing Spectrum of Systemic Therapies for Eosinophilic Granulomatosis with Polyangiitis from 2006-2023

    Lynn Fussner1, Christian Pagnoux2, David Cuthbertson3, Thomas Corbridge4, Nader Khalidi5, Curry Koening6, Carol Langford7, Carol McAlear8, Paul Monach9, Larry Moreland10, Rennie Rhee8, Philip Seo11, Anat Shavit12, Jared Silver13, Ulrich Specks14, Kenneth Warrington14, Michael Wechsler15 and Peter Merkel8, and for the Vasculitis Clinical Research Consortium, 1The Ohio State University, Columbus, OH, 2Mount Sinai Hospital, Toronto, ON, Canada, 3University of South Florida, Tampa, FL, 4US Value Evidence and Outcomes, GSK, Durham, NC, 5McMaster University, Hamilton, ON, Canada, 6University of Texas Dell Medical School, Austin, TX, 7Cleveland Clinic, Moreland Hills, OH, 8University of Pennsylvania, Philadelphia, PA, 9VA Boston Healthcare System, Boston, MA, 10University of Colorado, Denver, CO, 11Johns Hopkins University, Baltimore, MD, 12BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 13US Medical Affairs - Respiratory, GSK, Durham, 14Mayo Clinic, Rochester, MN, 15National Jewish Health, Denver, CO

    Background/Purpose: The emergence of biologic therapies targeting eosinophils via the IL-5 pathway provided new options for treatment in eosinophilic granulomatosis with polyangiitis (EGPA). There has…
  • Abstract Number: 1604 • ACR Convergence 2024

    Utilizing Machine Learning with Claims Data to Diagnose and Quantify the Prevalence of Eosinophilic Granulomatosis with Polyangiitis

    Peter Merkel1, Peter Baudy2, Donna Carstens2, Benjamin North3, Mahvish Danka3, Stephanie Roy3, Hanna Marshall3 and Geoffrey Chupp4, 1University of Pennsylvania, Philadelphia, PA, 2Respiratory & Immunology US Medical, AstraZeneca, Wilmington, 3IQVIA, Philadelphia, 4School of Medicine, Yale University, New Haven

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis that can present indolently. This can lead to a delay in diagnosis and treatment. This study…
  • Abstract Number: 1605 • ACR Convergence 2024

    Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis

    Peter Merkel1, David Jayne2, Ulrich Specks3, Christian Pagnoux4, Parameswaran Nair5, Nader Khalidi5, Arnaud Bourdin6, Lena Börjesson Sjö7, Sofia Necander7, Anat Shavit8, Claire Walton9 and Michael Wechsler10, 1University of Pennsylvania, Philadelphia, PA, 2University of Cambridge, Cambridge, United Kingdom, 3Mayo Clinic, Rochester, MN, 4Mount Sinai Hospital, Toronto, ON, Canada, 5McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, 6Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France, 7Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 8BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 9Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 10National Jewish Health, Denver, CO

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis. In the Phase 3, double-blind,…
  • Abstract Number: 1606 • ACR Convergence 2024

    Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data

    Paul Dolin1, Anat Shavit1, Karina A. Keogh2, Jennifer Rowell3, Chris Edmonds4, James M. Eudicone5, Amanda M. Moore6, Melissa Wilson7, Kinwei A. Chan6, Thomas Peer8 and Stephanie Y. Chen9, 1BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, 3Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, 4Market Access and Pricing, AstraZeneca, Gaithersburg, MD, 5Real World Science and Analytics, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, 6TriNetX, Cambridge, MA, 7TriNetX, Durham, NC, 8TriNetX, Farmington, NY, 9BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by chronic necrotizing vasculitis. Conventional therapy (oral glucocorticoids [OGC] ± immunosuppressants), mepolizumab, and…
  • Abstract Number: 1607 • ACR Convergence 2024

    Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

    Sebastian Klapa1, Sabrina Arnold2, Antje Müller2, Andreas Koch3, Anja Staehle4, Wataru Kähler3, Harry Heidecke5, Gabriela Riemekasten2 and Peter Lamprecht2, 1University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, 2University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, 3Christian-Albrechts-University Kiel, Institute of Experimental Medicine, Kiel, Germany, 4University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, 5CellTrend GmbH, Luckenwalde, Germany

    Background/Purpose: Complement activation has been shown to play an important role in the pathogenesis of the two major anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) variants,…
  • Abstract Number: 1608 • ACR Convergence 2024

    Interstitial Lung Disease in ANCA-associated Vasculitis: A Retrospective Study of Clinical Characteristics, Radiographic Features, and Outcomes

    Janelle Castellino1, Matas Orentas2, Joshua Moran3, Joshlean Fair1, Yanyu Zhang4 and Aleksandra Bukiej5, 1Rush University Medical Center, Chicago, IL, 2RUMC, Chicago, IL, 3Rush University Medical Center - IM Residency, Chicago, IL, 4Rush University Medical Center, Chicago, 5Rush University Medical Center, River Forest, IL

    Background/Purpose: Interstitial lung disease (ILD) is a significant manifestation of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and…
  • Abstract Number: 1611 • ACR Convergence 2024

    Impact of Mepolizumab on Patient-reported Outcomes in Eosinophilic Granulomatosis with Polyangiitis by Using the ANCA-associated Vasculitis Patient-reported Outcomes (AAV-PRO) Questionnaire: A European Multicentre Prospective Study

    Paolo Delvino1, Luca Quartuccio2, Joanna Robson3, Federico Alberici4, Diego Bagnasco5, Alvise Berti6, Marco Caminati7, Marta Camoni8, Maria Cid9, Edoardo Conticini10, Giulia Costanzo11, Claire de Moreuil12, Stefano Del Giacco11, Georgina Espigol-Frigole13, Virginia V Ferretti14, Franco Franceschini15, Luca Iorio16, Anna Kernder17, Catherine Klersy14, Alberto Lo Gullo18, Laura Losappio19, Elena Manna20, Matteo Maule21, Carlomaurizio Montecucco22, Negrini Simone23, Roberto Padoan24, Francesca Regola25, Luisa Ricciardi26, Jan Schroeder19, Benjamin Terrier27, Paola Toniati28, Elena Treppo2, Maria-Letizia Urban29, Augusto Vaglio30, Giacomo Emmi31 and Sara Monti32, and European EGPA Study Group, 1University of Milano-Bicocca, Milan, Milan, Italy, 2Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, 3UWE Bristol, Bristol, United Kingdom, 4Nephrology Unit, University of Brescia, ASST Spedali Civili, University of Brescia, Brescia, Italy, Brescia, Italy, 5Allergy and Respiratory Diseases, Department of Internal Medicine (DIMI), IRCCS Policlinico San Martino, Genoa, Italy, 6University of Trento, Rochester, Italy, 7Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, 8Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy, 9Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain, 10University of Siena, Siena, Siena, Italy, 11Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy, 12Service de médecine interne, CHU de Brest, Brest, France, 13Hospital Clinic de Barcelona, Barcelona, Spain, 14Biostatistcs & Clinical Trial Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy, 15Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, 16Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, Padova, Italy, 17HHU Dusseldorf, Dusseldorf, Germany, 18Rheumatology Unit, Papardo Hospital, Messina, Italy, 19Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milan, Milan, Italy, 20Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy, 21Asthma Center and Allergy Unit, Verona Integrated University Hospital, Verona, Verona, Italy, 22IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 23Department of Internal Medicine (DIMI), University of Genoa, Genoa, Genoa, Italy, 24Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, 25Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia and University of Brescia, Brescia, Italy, 26Allergy and Immunology Unit, Department of Clinical and Experimental Medicine, G. Martino Teaching Hospital, University of Messina, Messina, Messina, Italy, 27Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 28Spedali civili, 25123, Italy, 29Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 30Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Florence, Italy, 31University of Trieste, Trieste, Italy, 32IRCCS Istituto Auxologico Italiano, Milan, Italy

    Background/Purpose: Mepolizumab (MEPO) proved its efficacy in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in the randomized controlled MIRRA trial. The ANCA-associated vasculitis patient-reported…
  • Abstract Number: 0827 • ACR Convergence 2024

    Oral Corticosteroid-Sparing Effects of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Results up to 7.4 Years from the Long-Term Access Programme

    Paneez Khoury1, Jared Silver2, Gerhard Wolff3, Robert Price4, Rejina Verghis5, Emmeline Igboekwe2 and Michael E Wechsler6, 1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 2US Medical Affairs-Respiratory, GSK, Durham, 3Clinical Development-Respiratory, GSK, Collegeville, 4Biostatistics, GSK, Stevenage, United Kingdom, 5Biostatistics, Development Respiratory, GSK, Brentford, United Kingdom, 6Department of Medicine, National Jewish Health, Denver, CO

    Background/Purpose: EGPA is a severe, rare, relapsing/remitting inflammatory disease, in which chronic or high oral corticosteroid (OCS) doses lead to adverse effects, adding to disease…
  • Abstract Number: 2000 • ACR Convergence 2024

    Induction of Systemic Inflammatory Diseases with Dupilumab Therapy

    Jeanne Tisseau des Escotais1, Camille Taille2, Julie Merindol3, Matthieu Groh4, Perrine SMETS5, Amel Boudjemaa6, Alexandra Audemard7, Nabil Belfeki8, Philippe Bonniaud9, Chloe Comarmond10, Isabelle DELACROIX11, Charlotte Descours12, Lucile Grange13, Paul Legendre14, Nihal Martis15, Thomas Moulinet16, Béatrice Walls17, Laurent Chouchana1 and Benjamin Terrier18, 1Cochin, Paris, France, 2Bichat Hospital, Paris, France, 3Internal Medicine Department, University Hospital of Nice, Côte d'Azur University, Nice, Provence-Alpes-Côte d'Azur, France., Nice, France, 4Foch, Suresnes, France, 5Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, 6CHU créteil, Créteil, France, 7Tours, Tours, France, 8CH Melun, Melun, France, 9Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, 10Lariboisière University Hospital, Paris, France, 11CHI créteil, Créteil, France, 12CH Tours, Tours, France, 13CH Saint-Etienne, Saint-Etienne, France, 14Service Médecine Interne et Polyvalente, Centre Hospitaliers Le Mans, Le Mans, France, 15CH Nice, Nice, France, 16CHRU de Nancy, Vandœuvre-lès-Nancy, France, 17Paris, Paris, France, 18Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: Dupilumab is a monoclonal antibody directed against the alpha subunit of the interleukin (IL)-4 receptor, blocking interleukin (IL)-4 and IL-13 signaling. It is approved…
  • Abstract Number: 0828 • ACR Convergence 2024

    Efficacy of Eosinophil-Targeting Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis in the Phase 3 MANDARA Trial

    Peter Merkel1, David Jayne2, Ulrich Specks3, Christian Pagnoux4, Benjamin Terrier5, Bernhard Hellmich6, Sofia Necander7, Anat Shavit8, Claire Walton9 and Michael Wechsler10, 1University of Pennsylvania, Philadelphia, PA, 2University of Cambridge, Cambridge, United Kingdom, 3Mayo Clinic, Rochester, MN, 4Mount Sinai Hospital, Toronto, ON, Canada, 5Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 6Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, 7Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 8BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 9Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 10National Jewish Health, Denver, CO

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by small- to medium-vessel vasculitis, asthma and eosinophilia. In the head-to-head MANDARA trial…
  • Abstract Number: 2479 • ACR Convergence 2024

    Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices

    Michael E Wechsler1, Anna Kovalszki2, Jared Silver3, Brian Stone4, Lior Seluk5, Lynn Huynh6, Wilson da Costa Junior6, Mingchen Ye6, Jeremiah Hwee7, Mei Sheng Duh6, William McCann4 and Amy G. Edgecomb8, 1Department of Medicine, National Jewish Health, Denver, CO, 2Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 3US Medical Affairs - Respiratory, GSK, Durham, 4Allergy Partners, Asheville, NC, 5Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, 6Analysis Group, Boston, MA, 7Value Evidence and Outcomes, GSK, Mississauga, Canada, 8US Value, Evidence, & Outcomes, Anti-Infectives and Respiratory, GSK, Philadelphia

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a severe rare systemic inflammatory disease characterized by elevated blood eosinophil counts ≥1000 cells/µL and vasculitis of small-…
  • Abstract Number: 1254 • ACR Convergence 2024

    The Impact of Eosinophilic Granulomatosis with Polyangiitis on the Health-Related Quality of Life of Patients and Their Ability to Work: Evidence from a Real-World Survey in Clinical Practice

    Robert Spiera1, Paul Dolin2, Anat Shavit2, Jennifer Rowell3, Chris Edmonds4, Josefine Persson5, Danuta Kielar6, Daniel Mascia7, James Siddall7, Tia Pennant7, Fritha Hennessy7 and Stephanie Y. Chen8, 1Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 2BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 3Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, 4Market Access and Pricing, AstraZeneca, Gaithersburg, MD, 5Market Access and Pricing, AstraZeneca, Gothenburg, Sweden, 6Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom, 7Adelphi Real World, Bollington, United Kingdom, 8BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody-associated vasculitis that confers significant disease burden. This real-world study described the impact of…
  • Abstract Number: 2482 • ACR Convergence 2024

    Long-Term Safety of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pooled Results from Two Open-Label Extension Studies

    Gerhard Wolff1, Michael E Wechsler2, Jared Silver3, Robert Price4, Rejina Verghis5, Peter Weller6, Peter Merkel7, Thomas Corbridge8 and Paneez Khoury9, 1Clinical Development-Respiratory, GSK, Collegeville, 2Department of Medicine, National Jewish Health, Denver, CO, 3US Medical Affairs-Respiratory, GSK, Durham, 4Biostatistics, GSK, Stevenage, United Kingdom, 5Biostatistics, Development Respiratory, GSK, Brentford, United Kingdom, 6Beth Israel Deaconess Medical Center, Department of Medicine, Division of Allergy and Inflammation, Harvard Medical School, Boston, MA, 7Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 8US Value Evidence and Outcomes, GSK, Durham, NC, 9National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

    Background/Purpose: The 52-week Phase III MIRRA trial demonstrated the safety and efficacy of anti-IL-5 mepolizumab in patients with EGPA. However, longer-term safety data are limited.…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology